




Instance: composition-en-36d93771f3347f288be457a7d33515c7
InstanceOf: CompositionUvEpi
Title: "Composition for ammonaps Package Leaflet"
Description:  "Composition for ammonaps Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp37d7f47dc02119dc99dca2248168f511)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ammonaps"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What AMMONAPS is and what it is used for </li>
<li>What you need to know before you take AMMONAPS </li>
<li>How to take AMMONAPS </li>
<li>Possible side effects </li>
<li>How to store AMMONAPS </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ammonaps is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ammonaps is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AMMONAPS is prescribed to patients with urea cycle disorders. Patients with these rare disorders 
have a deficiency of certain liver enzymes and are therefore unable to eliminate nitrogen waste. 
Nitrogen is a building block of proteins, because of this, there is a build up of nitrogen in the body 
after eating protein. Nitrogen waste, in the form of ammonia, is especially toxic for the brain and 
leads, in severe cases, to reduced levels of consciousness and to coma.  </p>
<p>AMMONAPS helps the body to eliminate nitrogen waste, reducing the amount of ammonia in your 
body. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take AMMONAPS 
- if you are pregnant. 
- if you are breast-feeding. 
- if you are allergic to sodium phenylbutyrate or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor before taking AMMONAPS 
-<br />
if you have difficulty swallowing. AMMONAPS tablets can get stuck in the oesophagus and 
cause ulcers. If you have difficulty swallowing it is recommended to use AMMONAPS 
granules instead. 
- if you suffer from heart failure, a decrease in your kidney function or other diseases, where the 
retention of the sodium salt contained in this medicine, may make your condition worse. 
- if you have decreased kidney or liver function, since AMMONAPS is eliminated from the body 
through the kidney and liver. 
- when given to small children, since they may not be able to swallow the tablets and may choke. 
It is recommended to use AMMONAPS granules instead. </p>
<p>AMMONAPS must be combined with a diet reduced in proteins designed especially for you by the 
doctor and the dietician. You must follow this diet carefully. 
AMMONAPS does not completely prevent the occurrence of an acute excess of ammonia in the blood 
and is not appropriate for treating such a condition, which is a medical emergency. </p>
<p>If you require laboratory tests, it is important to remind your doctor that you are taking AMMONAPS, 
since sodium phenylbutyrate may influence certain laboratory test results. </p>
<p>Other medicines and AMMONAPS 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>It is especially important to tell your doctor if you are taking medicines containing:</p>
<ul>
<li>valproic acid (an antiepileptic drug),  </li>
<li>haloperidol (used in certain psychotic disorders),  </li>
<li>corticosteroids (cortisone-like medicines that are used to provide relief for inflamed areas of the 
body),  </li>
<li>probenecid (for treatment of hyperuricemia associated with gout). </li>
</ul>
<p>These medicines may change the effect of AMMONAPS and you will need more frequent blood 
controls. If you are uncertain if your medicines contain these substances, you should check with your 
doctor or pharmacist.  </p>
<p>Pregnancy and breast-feeding 
Do not use AMMONAPS if you are pregnant, because this medicine can harm your unborn baby. If 
you are a woman who could get pregnant, you must use reliable contraception, during treatment with 
AMMONAPS. 
Do not use AMMONAPS if you are breast-feeding, because this medicine can pass into the breast-
milk and harm your baby. </p>
<p>Driving and using machines 
No studies on the effects on the ability to drive and use machines have been performed. </p>
<p>AMMONAPS contains sodium 
Each AMMONAPS tablet contains 62 mg of sodium.  </p>
<p>Talk to your doctor or pharmacist if you need 6 or more tablets daily for a prolonged period, especially 
if you have been advised to follow a low salt (sodium) diet.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>Dosage 
The daily dose of AMMONAPS will be calculated from your protein tolerance, diet and body weight 
or body surface. You will need regular blood tests to determine the correct daily dose. Your doctor 
will tell you how many tablets you should take.  </p>
<p>Method of administration 
You should take AMMONAPS by mouth in equally divided doses with each meal (for example three 
times per day). You should take AMMONAPS with a large volume of water. </p>
<p>AMMONAPS must be taken with a special diet reduced in protein. </p>
<p>AMMONAPS tablets should not be given to children who are not able to swallow tablets. It is 
recommended that AMMONAPS granules are used instead. </p>
<p>You will need to have treatment and to follow a diet throughout your life, unless you have a successful 
liver transplantation. </p>
<p>If you take more AMMONAPS than you should 
Patients who have taken very high doses of AMMONAPS experienced:</p>
<ul>
<li>sleepiness, tiredness, light-headedness and less frequently confusion,  </li>
<li>headache,  </li>
<li>changes in taste (taste disturbances),  </li>
<li>decrease in hearing,  </li>
<li>disorientation,  </li>
<li>impaired memory, </li>
<li>worsening of existing neurological conditions. </li>
</ul>
<p>If you experience any of these symptoms, you should immediately contact your doctor or the nearest 
hospital emergency department for supportive treatment. </p>
<p>If you forget to take AMMONAPS 
You should take a dose as soon as possible with your next meal. Make sure that there are at least 
3 hours between two doses. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The frequency of possible side effects is listed below. </p>
<p>Very common:<br />
Affects more than 1 user in Common: <br />
Affects 1 to 10 users in Uncommon:<br />
Affects 1 to 10 users in 1,Rare:  </p>
<p>Affects 1 to 10 users in 10,Very rare: <br />
Affects less than 1 user in 10,Not known: <br />
Frequency cannot be estimated from the available data </p>
<p>Very common side effects: irregular menstrual periods and cessation of menstrual periods.<br />
If you are sexually active and your period stops altogether, do not assume that this is caused by 
AMMONAPS. If this occurs, please discuss it with your doctor, because the absence of your period 
may be caused by pregnancy (see Pregnancy and breast-feeding section above). </p>
<p>Common side effects: changes in number of blood cells (red cells, white cells and platelets), reduced 
appetite, depression, irritability, headache, fainting, fluid retention (swelling), changes in taste (taste 
disturbances), pain in the abdomen, vomiting, nausea, constipation, skin odour, rash, abnormal kidney 
function, weight gain, altered laboratory test values. </p>
<p>Uncommon side effects: deficiency in red blood cells due to bone marrow depression, bruising, altered 
heart rhythm, rectal bleeding, stomach irritation, stomach ulcer, inflammation of the pancreas. </p>
<p>If persistent vomiting occurs, you should contact your doctor immediately. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the bottle label after 
 EXP . The expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What AMMONAPS contains </p>
<ul>
<li>The active substance is sodium phenylbutyrate.<br />
Each tablet of AMMONAPS contains 500 mg of sodium phenylbutyrate. </li>
<li>The other ingredients are microcrystalline cellulose, magnesium stearate and colloidal 
anhydrous silica. </li>
</ul>
<p>What AMMONAPS looks like and contents of the pack 
AMMONAPS tablets are off-white, oval and embossed with  UCY 500 . </p>
<p>The tablets are packaged in plastic bottles with child-resistant caps. Each bottle contains 250 or 
500 tablets.  </p>
<p>Marketing Authorisation Holder<br />
Immedica Pharma AB 
SE-113 63 Stockholm 
Sweden </p>
<p>Manufacturer 
PATHEON France   BOURGOIN JALLIEU 
40 boulevard de Champaret 
BOURGOIN JALLIEU 
38France </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-36d93771f3347f288be457a7d33515c7
InstanceOf: CompositionUvEpi
Title: "Composition for ammonaps Package Leaflet"
Description:  "Composition for ammonaps Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp37d7f47dc02119dc99dca2248168f511)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ammonaps"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage AMMONAPS 
3. Sådan skal du tage AMMONAPS 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ammonaps is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ammonaps is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AMMONAPS ordineres til patienter, der lider af forstyrrelser i urinstofcyklus. Patienter med disse 
sjældne forstyrrelser mangler nogle bestemte leverenzymer og er derfor ikke i stand til at udskille 
kvælstofholdige affaldsstoffer. Kvælstof er en af byggestenene i proteiner, og derfor ophobes der 
kvælstof i kroppen, når man har indtaget proteiner. De kvælstofholdige affaldsstoffer findes i kroppen 
i form af ammoniak som er specielt giftigt for hjernen og i alvorlige tilfælde kan føre til 
bevidsthedsforstyrrelser og koma.  </p>
<p>AMMONAPS hjælper kroppen med at fjerne de kvælstofholdige affaldsstoffer og dermed reducere 
mængden af ammoniak i kroppen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke AMMONAPS 
- hvis du er gravid 
- hvis du ammer 
- hvis du er allergisk over for natriumphenylbutyrat eller et af de øvrige indholdsstoffer (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen før du tager AMMONAPS 
- hvis du har svært ved at synke. AMMONAPS tabletterne kan sidde fast i spiserøret og forårsage 
sår. Det anbefales, at du i stedet for anvender AMMONAPS granulat, hvis du har svært ved at 
synke tabletterne. 
- hvis du lider af hjertesvigt, nedsat nyrefunktion eller andre sygdomme, hvor ophobningen af det 
natriumsalt, der er i dette lægemiddel, kan forværre din tilstand. 
- hvis du har nedsat nyrefunktion eller leverfunktion, da AMMONAPS udskilles fra kroppen 
igennem nyrerne og leveren. 
- hvis AMMONAPS gives til små børn, da de måske ikke kan sluge tabletterne og kan kvæles. 
Det anbefales at bruge AMMONAPS granulat i stedet. </p>
<p>AMMONAPS skal kombineres med en lavproteindiæt, som udarbejdes specielt til dig af en læge eller 
en kostvejleder. Du skal følge denne diæt nøje. </p>
<p>AMMONAPS forhindrer ikke fuldstændigt, at en akut tilstand med for meget ammoniak i blodet 
opstår, og AMMONAPS er ikke egnet til behandling af en sådan nødsituation. </p>
<p>Hvis du skal have taget laboratorieprøver, er det vigtigt, at du fortæller det til lægen, at du tager 
AMMONAPS, da natriumphenylbutyrat kan påvirke resultaterne af bestemte laboratorieprøver.  </p>
<p>Brug af anden medicin sammen med AMMONAPS 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.  </p>
<p>Det er især vigtigt, at du fortæller det til din læge, hvis du tager medicin, som indeholder:</p>
<ul>
<li>valproinsyre (et antiepileptisk lægemiddel) </li>
<li>haloperidol (der anvendes til behandling af visse psykotiske lidelser) </li>
<li>kortikosteroider (kortisonlignende lægemidler, som anvendes til at lindre betændelsestilstande i 
kroppen) </li>
<li>probenecid (til behandling af forhøjet indhold af urinsyre i blodet i forbindelse med gigt 
(hyperurikæmi)) </li>
</ul>
<p>Disse lægemidler kan ændre virkningen af AMMONAPS, og du vil have behov for hyppigere kontrol 
af blodet. Spørg din læge eller på apoteket, hvis du er usikker på, om din medicin indeholder disse 
stoffer. </p>
<p>Graviditet og amning 
Tag ikke AMMONAPS, hvis du er gravid, da denne medicin kan skade det ufødte barn. Hvis du er 
kvinde, og du kan blive gravid, skal du bruge en sikker form for svangerskabsforebyggelse under 
behandlingen med AMMONAPS. </p>
<p>Tag ikke AMMONAPS, hvis du ammer, da denne medicin kan passere over i modermælken og skade 
dit barn. </p>
<p>Trafik- og arbejdssikkerhed 
Der er ikke lavet undersøgelser af virkningerne på evnen til at føre motorkøretøj eller betjene 
maskiner. </p>
<p>AMMONAPS indeholder natrium, hvor advarsel er påkrævet 
Hver AMMONAPS tablet indeholder 62 mg natrium. </p>
<p>Tal med lægen eller apotekspersonalet, hvis du i en længere periode skal tage 6 eller flere tabletter 
dagligt, især hvis du er blevet rådet til at følge en diæt, der har et lavt indhold af salt (natrium). </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på apoteket.  </p>
<p>Dosering 
Den daglige dosis AMMONAPS beregnes på baggrund af din proteintolerance, kost og legemsvægt 
eller legemsoverflade. Du skal derfor regelmæssigt have taget blodprøver for at finde den rigtige 
daglige dosis. Din læge vil fortælle dig, hvor mange tabletter du skal tage. </p>
<p>Indgivelsesmåde 
Du skal tage AMMONAPS gennem munden i ligeligt inddelte doser og sammen med hvert måltid (for 
eksempel tre gange om dagen). Du skal tage AMMONAPS sammen med en stor mængde vand. </p>
<p>AMMONAPS skal tages sammen med en særlig lavproteindiæt. </p>
<p>AMMONAPS tabletter bør ikke gives til børn, som ikke er i stand til at sluge tabletter. Det anbefales 
at anvende AMMONAPS granulat i stedet. </p>
<p>Du vil hele livet skulle have behandling og følge en særlig kostplan, medmindre du får foretaget en 
vellykket levertransplantation.   </p>
<p>Hvis du har taget for meget AMMONAPS 
Patienter, der har taget meget store doser AMMONAPS, oplever:</p>
<ul>
<li>søvnighed, træthed, svimmelhed og mindre hyppigt forvirring </li>
<li>hovedpine </li>
<li>smagsforstyrrelser </li>
<li>nedsat hørelse </li>
<li>desorientering </li>
<li>svækket hukommelse </li>
<li>forværring af eksisterende neurologiske tilstande. </li>
</ul>
<p>Hvis du oplever et af de nævnte symptomer, bør du straks kontakte din læge eller skadestuen på 
nærmeste hospital for at få understøttende behandling. </p>
<p>Hvis du har glemt at tage AMMONAPS 
Du skal tage en dosis så hurtigt som muligt sammen med dit næste måltid. Der skal være mindst 
3 timer mellem to doser. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Hyppigheden af mulige bivirkninger er anført herunder: </p>
<p>Meget almindelig: Forekommer hos mere end 1 bruger ud af Almindelig:<br />
Rammer fra 1 til 10 brugere ud af Ikke almindelig: 
Rammer fra 1 til 10 brugere ud af 1Sjælden: </p>
<p>Rammer fra 1 til 10 brugere ud af 10.Meget sjælden: 
Rammer færre end 1 bruger ud af 10.Ikke kendt:<br />
Hyppigheden kan ikke estimeres ud fra de tilgængelige data </p>
<p>Meget almindelige bivirkninger: uregelmæssige menstruationer og ophør af menstruationer. 
Hvis du er seksuelt aktiv, og dine menstruationer standser helt, må du ikke antage, at det skyldes 
AMMONAPS. Fortæl det til din læge, hvis dette sker, da menstruationsophøret kan skyldes, at du er 
gravid (se afsnittet herover om graviditet og amning).  </p>
<p>Almindelige bivirkninger: ændringer i antallet af blodlegemer (røde blodlegemer, hvide blodlegemer 
og blodplader), nedsat appetit, depression, irritabilitet, hovedpine, besvimelse, væskeophobning 
(hævelse), smagsforstyrrelser, mavesmerter, opkastning, kvalme, forstoppelse, unormal kropslugt, 
udslæt, unormal nyrefunktion, vægtstigning, ændrede resultater af laboratorieanalyser. </p>
<p>Ikke almindelige bivirkninger: mangel på røde blodlegemer som følge af knoglemarvsundertrykkelse, 
blå mærker, ændret hjerterytme, blødning fra endetarmen, maveirritation, mavesår, betændelse i 
bugspytkirtlen. </p>
<p>Ved vedvarende opkastninger skal du straks kontakte din læge. </p>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ammonaps"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ammonaps"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke AMMONAPS efter den udløbsdato, der står på pakningen og flaskeetiketten efter ”EXP”. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30°C. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>AMMONAPS indeholder:</p>
<ul>
<li>Aktivt stof: natriumphenylbutyrat.<br />
Hver tablet med AMMONAPS indeholder 500 mg natriumphenylbutyrat. </li>
<li>Øvrige indholdsstoffer: mikrokrystallinsk cellulose, magnesiumstearat og kolloid vandfri silica. </li>
</ul>
<p>Udseende og pakningsstørrelser 
AMMONAPS tabletter er off-white, ovale og påtrykt “UCY 500”. </p>
<p>Tabletterne er pakket i plastflasker med børnesikret låg. Hver flaske indeholder 250 eller 500 tabletter. </p>
<p>Indehaver af markedsføringstilladelsen 
Immedica Pharma AB 
SE-113 63 Stockholm 
Sverige </p>
<p>Fremstiller 
PATHEON France – BOURGOIN JALLIEU 
40 boulevard de Champaret 
BOURGOIN JALLIEU 
38Frankrig </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om AMMONAPS på det Europæiske Lægemiddelagenturs<br />
hjemmeside http://www.ema.europa.eu/.  </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>AMMONAPS 940 mg/g granulat 
Natriumphenylbutyrat </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
- Lægen har ordineret AMMONAPS til dig personligt. Lad derfor være med at give det til andre. 
Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
- Kontakt lægen eller apotekspersonalet, hvis en bivirkning bliver værre, eller du får bivirkninger, 
som ikke er nævnt her. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-36d93771f3347f288be457a7d33515c7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ammonaps Package Leaflet for language en"
Description: "ePI document Bundle for ammonaps Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-36d93771f3347f288be457a7d33515c7"
* entry[0].resource = composition-en-36d93771f3347f288be457a7d33515c7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp36d93771f3347f288be457a7d33515c7"
* entry[=].resource = mp36d93771f3347f288be457a7d33515c7
                            
                    
Instance: bundlepackageleaflet-da-36d93771f3347f288be457a7d33515c7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ammonaps Package Leaflet for language da"
Description: "ePI document Bundle for ammonaps Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-36d93771f3347f288be457a7d33515c7"
* entry[0].resource = composition-da-36d93771f3347f288be457a7d33515c7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp36d93771f3347f288be457a7d33515c7"
* entry[=].resource = mp36d93771f3347f288be457a7d33515c7
                            
                    



Instance: mp36d93771f3347f288be457a7d33515c7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ammonaps"
Description: "ammonaps"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/99/120/001 (250 tablets)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "AMMONAPS is indicated as adjunctive therapy in the chronic management of urea cycle disorders,"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "ammonaps"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 36d93771f3347f288be457a7d33515c7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ammonaps"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ammonaps"

* subject = Reference(mp37d7f47dc02119dc99dca2248168f511)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ammonaps "ammonaps"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-36d93771f3347f288be457a7d33515c7) // ammonaps en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-36d93771f3347f288be457a7d33515c7) // ammonaps da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-36d93771f3347f288be457a7d33515c7
InstanceOf: List

* insert 36d93771f3347f288be457a7d33515c7ListRuleset
    